Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-1.16 |
-1.26 |
-0.1 |
-8.62% |
2024-03-14 |
2023-12 |
-0.82 |
-1.02 |
-0.2 |
-24.39% |
2023-11-08 |
2023-09 |
-0.92 |
-0.75 |
0.17 |
18.48% |
2023-08-08 |
2023-06 |
-1.13 |
-1.37 |
-0.24 |
-21.24% |
2023-05-09 |
2023-03 |
-1.08 |
-0.96 |
0.12 |
11.11% |
2023-03-14 |
2022-12 |
0 |
-0.96 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-28 |
B. Riley Securities |
Upgrade |
Buy |
Buy |
2023-09-26 |
B. Riley Securities |
Upgrade |
|
Buy |
2023-08-28 |
Mizuho |
Upgrade |
Buy |
Buy |
2023-08-08 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-07-10 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-07-05 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2020-12-03 |
BARBERICH TIMOTHY J |
Director |
218.00K |
Purchase |
2024-04-04 |
CALKINS DANIEL |
Chief Financial Officer |
8.54K |
Sale |
2018-09-27 |
FORRESTER ROBERT |
Chief Executive Officer |
231.23K |
Purchase |
2024-03-18 |
GAGNON ROBERT E |
Director |
27.39K |
Sale |
2018-09-27 |
KAUFFMAN MICHAEL G |
Director |
8.00K |
Stock Award(Grant) |
2021-01-05 |
NEUMANN FRANK |
Officer |
150.00K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Viking Global Investors, L.P. |
1.89M |
14.03M |
7.47% |
2023-06-29 |
BVF Inc. |
1.69M |
12.54M |
6.67% |
2023-06-29 |
Deerfield Management Company, L.P. (Series C) |
1.54M |
11.45M |
6.09% |
2023-06-29 |
Vivo Capital, LLC |
1.54M |
11.45M |
6.09% |
2023-06-29 |
Orbimed Advisors LLC. |
1.53M |
11.38M |
6.06% |
2023-06-29 |
Baker Brothers Advisors, LLC |
1.34M |
9.94M |
5.29% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
746.25K |
5.55M |
2.96% |
2023-06-29 |
Vanguard Extended Market Index Fund |
220.01K |
1.64M |
0.87% |
2023-06-29 |
Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund |
150.00K |
1.12M |
0.59% |
2023-05-30 |
Fidelity Extended Market Index Fund |
79.92K |
978.25K |
0.32% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
29.58K |
220.10K |
0.12% |
2023-05-30 |
Fidelity Total Market Index Fund |
26.63K |
326.00K |
0.11% |
Split |
Date |
1 : 12 |
2023-06-01 |